<DOC>
	<DOCNO>NCT02366546</DOCNO>
	<brief_summary>Following pre-treatment cyclophosphamide and/or fludarabine , NY-ESO-1-specific TCR gene transduce T lymphocyte transfer patient NY-ESO-1-expressing solid tumor .</brief_summary>
	<brief_title>Investigator Initiated Phase 1 Study TBI-1301</brief_title>
	<detailed_description>Following pre-treatment cyclophosphamide alone combination fludarabine , NY-ESO-1-specific TCR gene transduce T lymphocyte transfer HLA-A*02:01 HLA-A*02:06 positive patient solid tumor 1 ) unresectable , refractory standard therapy ( chemotherapy , radiotherapy , etc ) , 2 ) NY-ESO-1-expressing . The primary objective evaluate safety vivo kinetics , secondary evaluate clinical effect .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . Histologically cytologically confirm solid tumor 2 . Solid tumor , unresectable , refractory standard therapy ( chemotherapy , radiotherapy , etc ) 3 . HLAA*02:01 HLAA*02:06 positive 4 . NYESO1expression PCR immunohistochemistry 5 . ECOG Performance Status , 0 1 6 . Age &gt; =20 year consent 7 . No treatment ( surgery , chemotherapy , radiotherapy , etc . ) expect sufficient recovery treatment time lymphocytes collection gene transfer . 8 . Life expectancy &gt; =16 week consent 9 . No severe damage major organ ( bone marrow , heart , lung , liver , kidney , etc ) meet follow lab value criterion : WBC &gt; = 2,500/μL Hemoglobin &gt; = 8.0g/dL Platelets &gt; = 75,000/μL T. bilirubin &lt; 1.5 x ULN AST ( GOT ) , ALT ( GPT ) &lt; 3.0 x ULN Creatinine &lt; 1.5 x ULN 10 . Ability understand study content give write consent his/her free . 1 . The follow serious complication exclude study ; Unstable angina , cardiac infarction , heart failure Uncontrolled diabetes hypertension Active infection Obvious interstitial pneumonia lung fibrosis chest Xray Active autoimmune disease require steroid immunosuppressive therapy . 2 . Serious hypersensitivity 3 . Tumor cell invasion CNS 4 . Active multiple cancer 5 . Positive HBs antigen HBVDNA observe serum 6 . Positive HCV antibody HCVRNA observe serum 7 . Positive antibody HIV HTLV1 8 . Left Ventricular Ejection Fraction ( LVEF ) : &lt; = 50％ 9 . Percutaneous Oxygen saturation : &lt; 94％ 10 . History serious hypersensitivity reaction bovine murine derive substance . 11 . History hypersensitivity reaction drug use study . 12 . Psychological disorder drug dependency may impact consent . 13 . Pregnant female , lactate female ( except cease n't resume lactation ) female male patient agree practice adequate birth control consent study 14 . Clinically significant systemic illness judgment PI subinvestigator would compromise patient 's ability tolerate protocol therapy significantly increase risk complication .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Adoptive cell transfer</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>NY-ESO-1</keyword>
	<keyword>Esophageal cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Head neck cancer</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Synovial sarcoma</keyword>
	<keyword>TCR gene therapy</keyword>
</DOC>